Scorpion Capital shorts TransMedics, shares down
Short seller Scorpion Capital disclosed a short position in TransMedics Group Inc (NASDAQ:TMDX) accusing the organ transplant ...
Why TransMedics Group Stock Is Tanking Today
Shares of TransMedics Group (NASDAQ: TMDX) were tanking 14.3% lower as of 10:46 a.m. ET on Friday. The big sell-off came ...
Scorpion Capital shorts TransMedics, alleging fraud in report
Shares of TransMedics (TMDX) are falling after Scorpion Capital revealed its short position on the company Friday. The ...
TransMedics down 10% to $65.39 after Scorpion Capital short report
EST TransMedics (TMDX) down 10% to $65.39 after Scorpion Capital short reportStay Ahead of the Market:Discover outperforming stocks and ...
Kehoe Law Firm, P.C. Securities Investigation on Behalf of Investors of TransMedics Group Stock Following Critical Report - NASDAQ: TMDX
NDAQ:TMDX) Kehoe Law Firm, P.C. Securities Investigation on Behalf of Investors of TransMedics Group Stock Following Critical Report - NASDAQ: TMDX ...
TransMedics named as short idea with $0 target by Scorpion Capital
Scorpion Capital said in a newly-issued short report that in “20 years of shorting, TransMedics (TMDX) is the most extreme and grotesque ...
Eli Lilly in advanced talks to buy US cancer biotech for up to $2.5bn
Scorpion’s drug candidate inhibits a mutation that is a major driver of breast, gynaecological and head and neck cancers ...
TransMedics Shares Plunge Following Short Seller Allegations
The report further alleges that TransMedics has been involved in kickbacks, billing fraud, unreported device failures, and ...
Eli Lilly in talks to acquire Scorpion Therapeutics, FT says; Relay Therapeutics seesaws
Eli Lilly in talks to acquire cancer biotech Scorpion Therapeutics for $2.5 billion, with potential milestone payments.